Investment Rating - The report suggests an "Overweight" rating for humanoid robots, AI applications, innovative drugs, and new consumption sectors [5][19]. Core Insights - The report highlights a strong growth potential in humanoid robots, with a projected shipment of nearly 18,000 units globally by 2025, representing a year-on-year increase of 508% [5]. - AI applications are expected to maintain steady growth, supported by the Ministry of Industry and Information Technology's initiative to build a national computing network [5]. - The innovative drug sector is experiencing a shift towards platform capabilities, as evidenced by a significant partnership between Innovent Biologics and Eli Lilly, valued at over $8 billion [9]. - New consumption trends are emerging, with adjustments in CPI statistics reflecting the inclusion of new categories such as dishwashers and medical beauty services [5]. Summary by Category Humanoid Robots - Rating: Overweight - Technical Indicators: Strong - Growth Expectation: Medium, stable growth anticipated - Key Data: IDC forecasts a shipment of nearly 18,000 humanoid robots by 2025, a 508% increase year-on-year [5]. AI Applications - Rating: Neutral + Overweight - Technical Indicators: Weak, but stabilizing - Growth Expectation: Medium, slight downward adjustment expected - Key Data: The Ministry of Industry and Information Technology has initiated the construction of a national computing network [5]. Innovative Drugs - Rating: Overweight - Technical Indicators: Strong - Growth Expectation: Low, upward revision expected - Key Data: Significant partnership between Innovent Biologics and Eli Lilly, valued at over $8 billion, marks a new phase in China's innovative drug export strategy [9]. New Consumption - Rating: Overweight - Technical Indicators: Strong - Growth Expectation: Low, stable growth anticipated - Key Data: CPI adjustments include new consumption categories, indicating a shift in consumer behavior [5].

证券分析师 022-28451618 SAC NO：S1150511010016 cuijian@bhzq.com 晨会纪要（2026/02/24） 崔健 渤海证券研究所晨会纪要（2026.02.24） 固定收益研究 债市延续偏强震荡——利率债周报 行业研究 1-8 批国家药品集采平稳接续，基药目录管理办法印发——医药生物行业周报 证 券 研 究 报 告 晨 会 纪 要 请务必阅读正文之后的声明 渤海证券股份有限公司具备证券投资咨询业务资格 1 of 5 晨会纪要（2026/02/24） 固定收益研究 债市延续偏强震荡——利率债周报 王哲语（证券分析师，SAC NO：S1150524070001） 周 喜（证券分析师，SAC NO：S1150511010017） 李济安（证券分析师，SAC NO：S1150522060001） 统计区间：2026 年 2 月 6 日至 2026 年 2 月 12 日。 统计期内，一级市场共发行利率债 96 只，实际发行总额为 9643 亿元，节前发行规模依然较高，其中，国 债发行规模增加，专项债发行规模小幅减少。 4、二级市场：债市延续偏强震荡 统计期内债市延续偏强震荡特征， ...

各大券商分析师春节"连轴转" 每经记者｜王海慜 每经编辑｜何小桃 赵云 宋思艰 2026年马年春节假期，虽然A股休市，但资本市场却热度不减。 各大券商的分析师们开启"加班模式"，以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的连续七天新春专题路演，到中信证券聚焦AI大模 型的系列电话会，再到多家机构跟踪春节消费动态，头部与中小券商均紧抓假期窗口输出市场观点。 《每日经济新闻》记者注意到，今年春节加班路演已经成为各券商研究所的常态，无论是中小券商还是头部券商都在假期中继续"营业"，"加更"观点。 港股马年开市两天呈现结构性行情，2月20日开市首日AI大模型、机器人板块逆势大涨，创新药、氢能概念股表现亮眼。2月20日和23日，恒生科技指数 走势先抑后扬，迎来马年"开门红"。 同时业内预计，美国此次关税裁定落地利好非美市场资产，叠加A股春节效应的历史正向表现，市场对马年节后"红包行情"的延续抱有较高期待。 截图来源：网络 最近，兴业证券策略首席张启尧的春节路演计划表在圈内刷屏：从大年初一至初七，他和团队同事一起每天15:00准时与投资者连线。 这场名为"新春专题系列"的直播，内容涵盖港股情绪研究框架、20 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 每经记者｜王海慜 每经编辑｜赵云 2026年马年春节假期，虽然A股休市，但资本市场却热度不减。 各大券商分析师们开启"加班模式"，以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的 连续七天新春专题路演，到中信证券聚焦AI（人工智能）大模型的系列电话会，再到多家机构跟踪春 节消费动态，头部与中小券商均紧抓假期窗口输出市场观点。 港股马年开市两天呈现结构性行情，2月20日开市首日AI大模型、机器人板块逆势大涨，创新药、氢能 概念股表现亮眼。2月23日，港股大涨。截至收盘，恒生指数涨2.53%，恒生科技指数涨3.34%。 此外，业内预计，美国最高法院关税裁定利好非美市场资产，叠加A股春节效应的历史正向表现，市场 对马年春节后"红包行情"的延续抱有较高期待。 机器人、创新药大热 这场名为"新春专题系列"的直播，内容涵盖港股情绪研究框架、2026年十大产业趋势、全球估值比较、 全球产业映射、出海深度报告等多个维度。张启尧及其团队试图在春节假期这一A股市场"空窗期"，通 过高频的观点输出，抢占投资者的注意力高地。 这并非行业个例。多家机构 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

医药周报 20260223: 春节期间医药行业重点事件梳理 glmszqdatemark 医药行情回顾&分析&近期判断 1）行情回顾：节前一周（2.9-2.13）医药生物指数环比-0.81%，跑输创业板指数和沪深 300 指数。在所有行业中，节前一周（2.9-2.13）医药涨跌幅排在第 20 位。医药本周缩量 调整，节前交易平淡。结构上看，脑机接口方向表现不错。医药成交总额 4011.15 亿元， 沪深总成交额为 104636.79 亿元，医药成交额占比沪深总成交额比例为 3.83%（2013 年 以来成交额均值为 7.09%）。 2）原因分析：我们认为医药板块近期市场关注度较低，行业整体缺乏显著催化剂，行情仍 以结构性机会为主，前期内部的板块轮动也未能形成持续趋势。我们认为脑机接口或因侵 入式三类证进展预期等多重利好因素表现相对不错。近一段时间医药板块的行情持续验证 我们此前判断，创新产业链和科技创新四大"从 0 到 1"方向路都有演绎，创新药产业逻 辑强，核心标的逐步进入价值赔率区间，中长期维度强化布局。 3）近期观点：医药这轮产业时代底层逻辑是创新和出海，2025 年市场交易的是创新药通 过 BD 出海 ...

Core Viewpoint - The Hong Kong stock market showed strong performance during the Spring Festival holiday, providing a positive reference for the A-share market as it prepares to open. The performance of overseas assets and Hong Kong stocks during the holiday is expected to be a key indicator for sector rotation in the A-share market [1][9]. Group 1: Market Performance - The Hong Kong stock market experienced a significant rally, contributing to a positive atmosphere for the A-share market's opening [1][9]. - During the holiday, the Hong Kong stock index fluctuated but ultimately rose, while the U.S. stock index saw only slight increases [2][10]. - Gold prices showed a four-day winning streak, indicating a strong performance in the precious metals sector [2][11]. Group 2: Sector Highlights - The Hong Kong market displayed structural trends, with sectors such as technology, internet, consumer electronics, and lithium batteries leading the gains. Notable stocks included Meituan, Tencent, and Alibaba [3][11]. - The optical fiber and cable leader, Longi Fiber Optic, saw its stock price double this year, driven by increased demand for high-fiber-count cables due to AI data center construction [12]. - Shipping and port stocks rose significantly due to geopolitical tensions, with China Merchants Energy's stock increasing nearly 90% since the beginning of the year [12]. Group 3: Fund Performance - Several funds heavily invested in Hong Kong stocks saw substantial gains, particularly in sectors like AI hardware, gold, innovative pharmaceuticals, and oil transportation, with some stocks rising over 10% during the A-share market's closure [11][12]. - Some innovative pharmaceutical companies in Hong Kong, such as Hang Seng Biotechnology and Hang Seng Healthcare, reported year-to-date gains exceeding 10% [4][13]. Group 4: Future Outlook - Analysts expect structural opportunities in the A-share market to continue, with resource products and AI sectors remaining the main focus for capital [15]. - The ongoing geopolitical tensions are likely to sustain demand for gold, with expectations of a continued bull market for gold over the next 2-3 years [15][16]. - Investment strategies are suggested to focus on high-growth sectors like AI hardware and applications, as well as undervalued sectors that may experience fundamental improvements and valuation recovery [17].

Group 1 - The top three companies by Hong Kong Stock Connect holding ratio are Haotian International Investment (71.36%), China Telecom (71.32%), and Green Power Environmental (68.88%) [1][2] - Tencent Holdings, Xiaomi Group-W, and Meituan-W have seen the largest increases in holding amounts over the last five trading days, with increases of +1.391 billion, +983 million, and +931 million respectively [1][2] - The companies with the largest decreases in holding amounts over the last five trading days include WuXi Biologics (-481 million), Zijin Mining (-447 million), and Southern Hengsheng Technology (-344 million) [1][4] Group 2 - The latest holding ratios for the top 20 companies in Hong Kong Stock Connect show Haotian International Investment with 7.919 billion shares, China Telecom with 9.900 billion shares, and Green Power Environmental with 0.279 billion shares [2] - The top 10 companies with the largest increases in holding amounts over the last five trading days include China Petroleum & Chemical Corporation (+315 million) and Zhaoyi Innovation (+309 million) [2][4] - The top 10 companies with the largest decreases in holding amounts include Pop Mart (-294 million) and SenseTime-W (-277 million) [4]

阿里、腾讯、美团等被总结为建议调出的"老登恒生"成分股。同时，恒生生物科技指数也在当日逆市收 涨0.96%，另外，石油股也出现走强。 值得留意的是，虽然港股互联网主题ETF、恒生科技ETF等节前资金流入最多的ETF并未迎来涨势，但 表现强势的个股也有公募基金的布局身影，次新股以打新的方式布局，而表现强势板块则在此前已有主 动权益基金的加仓迹象。 2月22日，节后首个交易日，恒指和恒生科技虽然没有收涨，但AI概念股的涨势如期而至。 2月20日，港股三大指数集体收跌。其中，恒生科技收跌2.91%，恒生指数收跌1.10%，而恒生国企指数 收跌1.22%。相较于恒生科技的继续下挫，港股上市的AI概念次新股却迎来上涨，网友也出现了调整恒 生科技部分成分股的建议。 小米、中芯国际、比亚迪、腾讯、快手等成分股也在去年四季度被主动权益基金减持，不过，美团在去 年四季度得到主动权益基金增持超过1700万股。 石油、创新药板块走强 港股AI概念股大涨 截至2月20日收盘，智谱延续强势表现，收涨42.72%，报725港元；MiniMax也同样收涨14.52%，报970 港元。两大AI龙头盘中最高市值双双突破3000亿港元，与上市初 ...

Core Viewpoint - The article emphasizes the transformative potential of the pharmaceutical and healthcare industry, highlighting the integration of AI technology, the global expansion of Chinese pharmaceutical innovations, and the commitment to deepening investment in the sector as key drivers for future growth [3][4][6][7]. Group 1: AI Empowerment in Pharmaceutical Innovation - AI is reshaping the pharmaceutical industry by significantly reducing research and development cycles and costs, addressing traditional challenges of high investment and long timelines [4][5]. - The integration of AI in drug discovery, clinical trial design, and production processes is seen as a new paradigm that enhances the industry's productivity and innovation capabilities [4][5]. Group 2: Global Expansion of Chinese Pharmaceutical Innovations - 2025 is identified as a pivotal year for Chinese pharmaceutical companies, marking a transition from quantity to quality in global markets, with total foreign licensing transactions exceeding $130 billion and over 150 deals [6]. - Chinese companies are increasingly recognized as equal partners in global pharmaceutical competition, with significant collaborations such as the $12 billion partnership between Heng Rui Medicine and GSK [6]. Group 3: Commitment to Investment in the Pharmaceutical Sector - The investment landscape in the pharmaceutical sector is evolving, with a projected financing total of approximately 122.78 billion yuan in 2025, reflecting a 46.41% year-on-year increase [7]. - The focus remains on early-stage, innovative, and high-quality companies, particularly in areas like AI drug development and advanced medical devices, to foster growth and innovation [7][8].